Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) (Frankfurt: W1H, WKN: A3EKSZ) is advancing a novel approach to cancer therapy that could address significant unmet needs in oncology. In a recent BioMedWire Podcast, Chief Medical Officer Dr. Islam Mohamed detailed the company's lead drug candidate, ONC010, which targets the DNA repair enzyme polynucleotide kinase phosphatase (PNKP). This target represents a new frontier in the DNA damage response pathway, and the company's exclusive worldwide license to patented technology for therapeutic inhibition of PNKP positions it at the forefront of this emerging field.
The significance of ONC010 lies in its dual selectivity mechanisms, designed to enhance efficacy while minimizing toxicity. The first mechanism, synthetic lethality, exploits specific genetic vulnerabilities in cancer cells that have lost PTEN or SHP-1. By targeting PNKP, ONC010 aims to selectively kill cancer cells with these mutations while sparing healthy cells. The second mechanism involves nanoparticle delivery, which concentrates the drug within tumor tissue, further reducing systemic exposure and potential side effects. This combination could lead to a more precise and tolerable treatment option for patients with limited therapeutic alternatives.
Preclinical research conducted at the University of Alberta supports the potential of ONC010. In these studies, the nano-formulated PNKP inhibitor demonstrated single-agent antitumor activity, was tolerated at tested doses, and prolonged survival relative to controls. These findings are particularly encouraging as they suggest that ONC010 could be effective as a monotherapy, simplifying treatment regimens and reducing the need for combination therapies that often increase toxicity.
The planned first-in-human clinical program for ONC010 is a critical next step. If successful, it could validate PNKP as a viable clinical target and open new avenues for treating cancers with PTEN or SHP-1 deficiencies. This is especially important for patients who have not responded to existing therapies, as it offers a new mechanism of action that could overcome resistance.
Onco-Innovations' focus on PNKP inhibition is part of a broader trend in oncology toward targeted therapies that exploit specific molecular vulnerabilities. The company's mission to pursue the prevention and treatment of cancer through pioneering research aligns with the growing emphasis on precision medicine. As the clinical program progresses, the results will be closely watched by investors and the medical community alike, given the potential of PNKP as a novel target.
For more information about Onco-Innovations and its developments, visit the company's newsroom at https://ibn.fm/ONNVF. The full press release regarding the podcast can be accessed at https://ibn.fm/XgpMR. Additionally, details about BioMedWire and its communications platforms are available at https://www.BioMedWire.com, with terms of use and disclaimers at https://www.BioMedWire.com/Disclaimer.
